Duquesne Light Company Beaver Valley Power Station
P.O. Box 4
Shippingport, PA 15077-0004

March 22, 1991

JOHN D. SIEBER
Vice President - Nuclear Group (412) 393-5255

U. S. Nuclear Regulatory Commission
Attn: Document Control Desk
Washington, DC 20555

Subject: Beaver Valley Power Station, Unit No. 1 and No. 2
BV-1 Docket No. 50-334, License No. DPR-66
BV-2 Docket No. 50-412, License No. NPF-73
Fitness-For-Duty Program Six Month Report Supplement

By letter dated March 13, 1991, we provided the Fitness-For-Duty Program Six Month Report for the period July 1, 1990 through December 31, 1990. The attached supplement to the above report provides a summary of management actions as required by 10 CFR 26.71 (d).

If there are any questions concerning this report, please contact Ms. Pat Casasanta at (412) 393-5238.

Sincerely,

J. D. Sieber
Vice President
Nuclear Group

Attachment

cc: Mr. J. Beall, Sr. Resident Inspector
Mr. T. T. Martin, NRC Region I Administrator
Mr. A. W. DeAgazio, Project Manager

A027

SUMMARY OF MANAGEMENT ACTIONS

1. Problem Identified:

Beginning 10/90, Duquesne Light Company identified discrepancies with results reported on fourteen blind proficiency samples sent to Roche Biomedical. Investigation proved the following:

a. The blind samples supplied to the licensee were felt to be unstable.

b. Roche Laboratory's method of screening appeared to have failed. this was based on Roche obtaining GC/MS values greater than 1000 on repeat analysis.

c. It appeared, on one THC sample, that the antiserum used was too specific. The licensee's audit of Roche Biomedical indicated a low-bias on the analysis for THC earlier in 1990.

To arrive at the above conclusions, the licensee used the services of another DHHS certified laboratory and purchased Bio-Rad, FDA approved, blind samples. Using the split method, samples were sent to Roche Biomedical and another DHHS certified lab. Results and screening methods were compared and conclusions drawn to explain the false negative reports.

Solution Implemented:

To correct these problems, the licensee has initiated the services of Clinical Pathology Facility, Pittsburgh, PA, as its primary lab, and now purchase FDA approved blind proficiency samples for quality control.